Department for the Study of Obesity and Diabetes, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
Franco-Czech Laboratory for Clinical Research on Obesity, Third Faculty of Medicine, Prague, and Institut des Maladies Métaboliques et Cardiovasculaires, Université Toulouse III Paul Sabatier, Toulouse, France.
Int J Obes (Lond). 2018 Mar;42(3):405-411. doi: 10.1038/ijo.2017.260. Epub 2017 Oct 30.
BACKGROUND/OBJECTIVES: OxLDL-β2GPI complex has been suggested to have a role in the development of atherosclerosis and other inflammatory diseases. The aim of this study was to investigate the possible association of circulating oxLDL-β2GPI with obesity-induced inflammatory state of adipose tissue and related comorbidities as metabolic syndrome development.
SUBJECTS/METHODS: Two cohorts of subjects were examined in the study. Cohort I: 36 women with wide range of body mass index (17-48 kg m) and metabolic status (with or without metabolic syndrome (MS); cohort II: 20 obese women undergoing a dietary intervention (DI) consisting of 1-month very-low-calorie diet, and 5 months of weight-stabilization period. Serum levels of oxLDL-β2GPI were measured by enzyme-linked immunosorbent assay. Insulin sensitivity was evaluated by hyperinsulinemic-euglycemic clamp and homeostasis model assessment of insulin resistance. mRNA expression of macrophage markers was determined in both subcutaneous (SAT) and visceral (VAT) adipose tissue in cohort I and in SAT in cohort II.
Serum oxLDL-β2GPI levels were increased in obese subjects with MS compared to lean or obese without MS (obese with MS: 26.6±5.0 vs lean: 15.17±1.97, P<0.001; vs obese without MS: 16.36±2.89, P<0.05). Serum oxLDL-β2GPI correlated with MS indices (glucose, high-density lipoprotein, triglyceride and ureic acid) and with mRNA expression of macrophage markers in VAT. Weight-reducing DI decreased serum oxLDL-β2GPI levels together with lipid parameters and the mRNA expression of inflammatory markers in SAT.
OxLDL-β2GPI seems to be an important marker of visceral adipose tissue inflammation and possibly a factor contributing to insulin resistance and metabolic syndrome development in obese patients.
背景/目的：氧化低密度脂蛋白-β2 糖蛋白复合物（oxLDL-β2GPI）被认为在动脉粥样硬化和其他炎症性疾病的发展中具有作用。本研究旨在探讨循环 oxLDL-β2GPI 与肥胖引起的脂肪组织炎症状态及相关并发症（如代谢综合征的发展）之间的可能关联。
受试者/方法：本研究检查了两个队列的受试者。队列 I：36 名女性，体重指数（BMI）范围广泛（17-48kg/m²），代谢状况（有或没有代谢综合征（MS））；队列 II：20 名肥胖女性接受饮食干预（DI），包括 1 个月的极低热量饮食和 5 个月的体重稳定期。通过酶联免疫吸附试验（ELISA）测定血清 oxLDL-β2GPI 水平。通过高胰岛素-正葡萄糖钳夹和稳态模型评估胰岛素抵抗来评估胰岛素敏感性。在队列 I 中测定了皮下（SAT）和内脏（VAT）脂肪组织以及队列 II 中 SAT 中巨噬细胞标志物的 mRNA 表达。
与 BMI 正常或肥胖但无 MS 的受试者相比，MS 肥胖受试者的血清 oxLDL-β2GPI 水平升高（MS 肥胖组：26.6±5.0 与 BMI 正常组：15.17±1.97，P<0.001；与 BMI 正常或肥胖但无 MS 组：16.36±2.89，P<0.05）。血清 oxLDL-β2GPI 与 MS 指标（血糖、高密度脂蛋白、甘油三酯和尿酸）以及 VAT 中巨噬细胞标志物的 mRNA 表达相关。减重 DI 降低了血清 oxLDL-β2GPI 水平以及 SAT 中脂质参数和炎症标志物的 mRNA 表达。
oxLDL-β2GPI 似乎是内脏脂肪组织炎症的重要标志物，可能是肥胖患者胰岛素抵抗和代谢综合征发展的一个因素。
Zotero 插件